A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI).

Takeshi Yamada,Tomohiro Nishina,Junichiro Nasu,Toshihiko Matsumoto,Yasuhiro Yuasa,Takeshi Shiraishi,Hiroaki Nagano,Ichiro Moriyama,Toshiyoshi Fujiwara,Masashi Miguchi,Ryosuke Yoshida,Kimiyasu Nosaka,Hiroaki Tanioka,Takeshi Nagasaka,Yasuro Kurisu,Michiya Kobayashi,Kenji Tsuchihashi,Michio Inukai,Takashi Kikuchi,Katsunori Shinozaki

A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI).

2020

134Background: FOLFOXIRI-Bmab has been recognized as one of the standard first-line treatments for mCRC. We conducted a single arm, multicenter, phase II study to assess the efficacy and safety of ...

Keywords:

Internal medicine
FOLFOXIRI
Phases of clinical research
Medicine
Chemotherapy
Oncology
Colorectal cancer
Bevacizumab
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations